These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 34177383)

  • 1. Patient Preferences for Time and Location of Infusible Therapies in Multiple Sclerosis and Neuroimmunologic Disorders.
    Rath L; Campagna MP; Stankovich J; Ellis J; Jokubaitis V; McCarthy D; Nesbitt C; Yeh WZ; Zhong M; Wesselingh R; Monif M; Richards J; Minh VB; Skibina O; Butzkueven H; van der Walt A
    Int J MS Care; 2021; 23(3):114-118. PubMed ID: 34177383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fast and safe: Optimising multiple sclerosis infusions during COVID-19 pandemic.
    Rath L; Bui MV; Ellis J; Carey J; Baker J; Taylor L; Fernando H; Taylor N; Savage P; Richards J; Zhong M; Kalincik T; Skibina O; Wesselingh R; Nguyen AL; Monif M; Butzkueven H; van der Walt A
    Mult Scler Relat Disord; 2021 Jan; 47():102642. PubMed ID: 33321356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Qualitative factors shaping MS patients' experiences of infusible disease-modifying drugs: a critical incident technique analysis.
    Larsen JL; Schäfer J; Nielsen HH; Vestergaard Rasmussen P
    BMJ Open; 2020 Aug; 10(8):e037701. PubMed ID: 32819993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies.
    Mayer L; Kappos L; Racke MK; Rammohan K; Traboulsee A; Hauser SL; Julian L; Köndgen H; Li C; Napieralski J; Zheng H; Wolinsky JS
    Mult Scler Relat Disord; 2019 May; 30():236-243. PubMed ID: 30844611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient and physician perception of the infusion process of the biologic agents abatacept, infliximab, and rituximab for the treatment of rheumatoid arthritis.
    Yazici Y; McMorris BJ; Darkow T; Rosenblatt LC
    Clin Exp Rheumatol; 2009; 27(6):907-13. PubMed ID: 20149304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The wearing-off phenomenon of ocrelizumab in patients with multiple sclerosis.
    Toorop AA; van Lierop ZYGJ; Strijbis EMM; Teunissen CE; Barkhof F; Uitdehaag BMJ; van Kempen ZLE; Killestein J
    Mult Scler Relat Disord; 2022 Jan; 57():103364. PubMed ID: 35158470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful management of a neurology infusion practice.
    Foley JF; Dunne AM
    Int J MS Care; 2011; 13(2):95-104. PubMed ID: 24453711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ocrelizumab Treatment in Patients with Primary Progressive Multiple Sclerosis: Short-term Safety Results from a Compassionate Use Programme in Germany.
    Rauer S; Hoshi MM; Pul R; Wahl M; Schwab M; Haas J; Ellrichmann G; Krumbholz M; Tackenberg B; Saum KU; Buck F; Leemhuis J; Kretschmann A; Aktas O
    Clin Neurol Neurosurg; 2020 Oct; 197():106142. PubMed ID: 32920498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial.
    Wolinsky JS; Arnold DL; Brochet B; Hartung HP; Montalban X; Naismith RT; Manfrini M; Overell J; Koendgen H; Sauter A; Bennett I; Hubeaux S; Kappos L; Hauser SL
    Lancet Neurol; 2020 Dec; 19(12):998-1009. PubMed ID: 33129442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bisphosphonate infusions: patient preference, safety and clinic use.
    Chern B; Joseph D; Joshua D; Pittman K; Richardson G; Schou M; Lowe S; Copeman M; De Abreu Lourenco R; Lynch K
    Support Care Cancer; 2004 Jun; 12(6):463-6. PubMed ID: 15088136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world cost of treatment for multiple sclerosis patients initiating and receiving infused disease-modifying therapies per recommended label in the United States.
    Nicholas J; Halpern R; Ziehn M; Peterson-Brandt J; Leszko M; Deshpande C
    J Med Econ; 2020 Aug; 23(8):885-893. PubMed ID: 32338098
    [No Abstract]   [Full Text] [Related]  

  • 12. Willingness to pay to assess patient preferences for therapy in a Canadian setting.
    Marra CA; Frighetto L; Goodfellow AF; Wai AO; Chase ML; Nicol RE; Leong CA; Tomlinson S; Ferreira BM; Jewesson PJ
    BMC Health Serv Res; 2005 Jun; 5():43. PubMed ID: 15941474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of delaying ocrelizumab dosing in multiple sclerosis due to COVID-19 pandemics on clinical and laboratory effectiveness.
    Barun B; Gabelić T; Adamec I; Babić A; Lalić H; Batinić D; Krbot Skorić M; Habek M
    Mult Scler Relat Disord; 2021 Feb; 48():102704. PubMed ID: 33370649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ocrelizumab initiation in patients with MS: A multicenter observational study.
    Ellwardt E; Rolfes L; Klein J; Pape K; Ruck T; Wiendl H; Schroeter M; Zipp F; Meuth SG; Warnke C; Bittner S
    Neurol Neuroimmunol Neuroinflamm; 2020 Jul; 7(4):. PubMed ID: 32273482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Work Productivity Outcomes Associated with Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis.
    Neuberger EE; Abbass IM; Jones E; Engmann NJ
    Neurol Ther; 2021 Jun; 10(1):183-196. PubMed ID: 33244713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Patient/rheumatologist evaluation of infusion treatment for rheumatoid arthritis].
    Willeke P; Becker H; Wassenberg S; Pavenstädt H; Jacobi AM
    Z Rheumatol; 2011 Apr; 70(3):232-4, 236-8. PubMed ID: 21359555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is home-based therapy in Fabry disease the answer to compelling patients' needs during the COVID-19 pandemic? Survey results from the Polish FD Collaborative Group.
    Kusztal M; Kłopotowski M; Bazan-Socha S; Błażejewska-Hyżorek B; Pawlaczyk K; Oko A; Krajewska M; Nowicki M
    Adv Clin Exp Med; 2021 Apr; 30(4):449-454. PubMed ID: 33908195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allergic and nonallergic delayed infusion reactions during natalizumab therapy.
    Hellwig K; Schimrigk S; Fischer M; Haghikia A; Müller T; Chan A; Gold R
    Arch Neurol; 2008 May; 65(5):656-8. PubMed ID: 18474743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natalizumab for induction of remission in Crohn's disease.
    Macdonald JK; McDonald JW
    Cochrane Database Syst Rev; 2006 Jul; (3):CD006097. PubMed ID: 16856112
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.